Abstract
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have